NCT04091399View on ClinicalTrials.gov

First-in-man Study of Adult Patients Suffered From Alveolar Osteitis Treated Using Stomatological Tamponade Contipro

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 11, 2015

Primary Completion Date

February 12, 2016

Study Completion Date

February 12, 2016

Conditions
Alveolar Osteitis
Interventions
DRUG

Stamatological tamponade Contipro

The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.

Trial Locations (11)

41301

DV Dent s.r.o., Roudnice nad Labem

50005

University Hospital Hradec Králové, Department of Dentistry, Hradec Králové

50601

Dentine s.r.o., Jičín

51773

FSmile s.r.o., Opočno

53002

Dentpra, Pardubice

Mojmír Strnad, Pardubice

53009

MEDIKAP, Pardubice

54401

Prouzovi s.r.o., Dvůr Králové nad Labem

60200

IchtysDent s.r.o, Brno

62500

University Hospital Brno, Clinic of Oral, Maxillary and Facial Surgery, Brno

400 01

Enta Dent s.r.o, Ústí nad Labem

Sponsors
All Listed Sponsors
lead

Contipro Pharma a.s.

OTHER

NCT04091399 - First-in-man Study of Adult Patients Suffered From Alveolar Osteitis Treated Using Stomatological Tamponade Contipro | Biotech Hunter | Biotech Hunter